Tag - MAAT

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Tag - MAAT

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

Subscribe